- Home
- KYMR vs JBLU Comparison
KYMR vs JBLU Comparison
Compare KYMR & JBLU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KYMR
- JBLU
- Stock Information
- Founded
- KYMR 2015
- JBLU 1998
- Country
- KYMR United States
- JBLU United States
- Employees
- KYMR N/A
- JBLU N/A
- Industry
- KYMR Medicinal Chemicals and Botanical Products
- JBLU Air Freight/Delivery Services
- Sector
- KYMR Health Care
- JBLU Consumer Discretionary
- Exchange
- KYMR Nasdaq
- JBLU Nasdaq
- Market Cap
- KYMR 2.7B
- JBLU 2.1B
- IPO Year
- KYMR 2020
- JBLU N/A
- Fundamental
- Price
- KYMR $36.81
- JBLU $7.01
- Analyst Decision
- KYMR Buy
- JBLU Sell
- Analyst Count
- KYMR 15
- JBLU 13
- Target Price
- KYMR $55.27
- JBLU $6.38
- AVG Volume (30 Days)
- KYMR 456.1K
- JBLU 28.0M
- Earning Date
- KYMR 02-27-2025
- JBLU 01-28-2025
- Dividend Yield
- KYMR N/A
- JBLU N/A
- EPS Growth
- KYMR N/A
- JBLU N/A
- EPS
- KYMR N/A
- JBLU N/A
- Revenue
- KYMR $87,563,000.00
- JBLU $9,279,000,000.00
- Revenue This Year
- KYMR N/A
- JBLU $7.06
- Revenue Next Year
- KYMR $32.89
- JBLU N/A
- P/E Ratio
- KYMR N/A
- JBLU N/A
- Revenue Growth
- KYMR 86.92
- JBLU N/A
- 52 Week Low
- KYMR $29.24
- JBLU $4.50
- 52 Week High
- KYMR $53.27
- JBLU $8.31
- Technical
- Relative Strength Index (RSI)
- KYMR 42.51
- JBLU 50.60
- Support Level
- KYMR $36.67
- JBLU $6.22
- Resistance Level
- KYMR $38.24
- JBLU $7.83
- Average True Range (ATR)
- KYMR 1.78
- JBLU 0.37
- MACD
- KYMR 0.06
- JBLU 0.10
- Stochastic Oscillator
- KYMR 51.81
- JBLU 54.70
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.
About JBLU JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The operating segments of company are Domestic & Canada, Caribbean & Latin America and Atlantic. Majority of revenue is generated from Domestic & Canada segment.